Vicarious Surgical prices $5.9 million registered direct offering

Vicarious Surgical Inc. (NYSE: RBOT) announced it entered into a securities purchase agreement with an institutional investor for a registered direct offering expected to generate gross proceeds of approximately $5.9 million.

The robotics technology company agreed to sell 1.15 million shares of Class A common stock or pre-funded warrants at a combined effective purchase price of $5.10 per share with accompanying warrants. Pre-funded warrants are priced at $5.0999 with accompanying warrants to purchase two shares of Class A common stock.

The offering includes Series A and Series B warrants to purchase up to 1.15 million shares each of Class A common stock. The warrants will be exercisable upon stockholder approval, expire five years from approval date, and carry an exercise price of $5.10 per share. Series B warrants include a provision allowing the company to repurchase them for $0.01 per underlying share upon reaching certain stock price and volume milestones.

Lake Street Capital Markets serves as the exclusive placement agent for the offering, which is expected to close around October 9, 2025, subject to customary closing conditions including NYSE authorization of a supplemental listing application.

Vicarious Surgical plans to use proceeds for general corporate purposes, including working capital, capital expenditures, or research and development expenses. The shares and pre-funded warrants are offered under a previously filed shelf registration statement, while the warrants are being issued in a concurrent private placement.

The Waltham, Massachusetts-based company develops surgical robotics technology designed to enable minimally invasive procedures using human-like surgical robots.

You May Also Be Interested In

• Greenland Mines releases first S-K 1300 resource estimate for Sarfartoq
• ANI Pharmaceuticals adds Henry Gosebruch to its board
• FibroBiologics adds sports agent Leigh Steinberg to its board